Resumo

APARICIO HERNANDEZ, R.; GARCIA LUQUE, A.; PEREZ MORAN, M.J.  e  SANCHEZ LOPEZ, P.. Possitive assesment of drugs: march, April and May 2015. Sanid. Mil. [online]. 2015, vol.71, n.3, pp.186-195. ISSN 1887-8571.  https://dx.doi.org/10.4321/S1887-85712015000300006.

The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in March, April and May of 2015, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

Palavras-chave : Atazanavir / Cobicistat; Evotaz^®; Cloruro de lutecio; 177LU; Lumark^®; Dinutuxima; Unituxin^®; Edoxaban; Lixiana^®; Empagliflozina/metformina; Synjardy^®; Evolocumab; Repatha^®; Fenilefrina / ketorolaco; Omidria^®; Lenvatinib; Lenvima^®; Netupitant/ palonosetron; Akynzeo^®; Nivolumab; Opdivo^®; Nivolumab; Nivolumab BMS^®; Pembrolizumab; Keytruda^®; Tasimelteon; Hetlioz^®; Vacuna frente al virus del papiloma humano nonavalente; Gardasil 9^®.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )